Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis.
Grigoryan A, Zacharaki D, Balhuizen A, Côme CR, Garcia AG, Hidalgo Gil D, Frank AK, Aaltonen K, Mañas A, Esfandyari J, Kjellman P, Englund E, Rodriguez C, Sime W, Massoumi R, Kalantari N, Prithiviraj S, Li Y, Dupard SJ, Isaksson H, Madsen CD, Porse BT, Bexell D, Bourgine PE. Grigoryan A, et al. Among authors: bexell d. Sci Transl Med. 2022 Oct 12;14(666):eabm6391. doi: 10.1126/scitranslmed.abm6391. Epub 2022 Oct 12. Sci Transl Med. 2022. PMID: 36223446
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D. Mohlin S, et al. Among authors: bexell d. EMBO Mol Med. 2019 Aug;11(8):e10058. doi: 10.15252/emmm.201810058. Epub 2019 Jul 16. EMBO Mol Med. 2019. PMID: 31310053 Free PMC article.
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma.
Hansson K, Radke K, Aaltonen K, Saarela J, Mañas A, Sjölund J, Smith EM, Pietras K, Påhlman S, Wennerberg K, Gisselsson D, Bexell D. Hansson K, et al. Among authors: bexell d. Sci Transl Med. 2020 Sep 23;12(562):eaba4434. doi: 10.1126/scitranslmed.aba4434. Sci Transl Med. 2020. PMID: 32967973
Anti-tumor effects of rigosertib in high-risk neuroblastoma.
Radke K, Hansson K, Sjölund J, Wolska M, Karlsson J, Esfandyari J, Pietras K, Aaltonen K, Gisselsson D, Bexell D. Radke K, et al. Among authors: bexell d. Transl Oncol. 2021 Aug;14(8):101149. doi: 10.1016/j.tranon.2021.101149. Epub 2021 Jun 9. Transl Oncol. 2021. PMID: 34118691 Free PMC article.
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance.
Mañas A, Aaltonen K, Andersson N, Hansson K, Adamska A, Seger A, Yasui H, van den Bos H, Radke K, Esfandyari J, Bhave MS, Karlsson J, Spierings D, Foijer F, Gisselsson D, Bexell D. Mañas A, et al. Among authors: bexell d. Sci Adv. 2022 Oct 28;8(43):eabq4617. doi: 10.1126/sciadv.abq4617. Epub 2022 Oct 28. Sci Adv. 2022. PMID: 36306349 Free PMC article.
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy.
Valind A, Verhoeven BM, Enoksson J, Karlsson J, Christensson G, Mañas A, Aaltonen K, Jansson C, Bexell D, Baryawno N, Gisselsson D, Hagerling C. Valind A, et al. Among authors: bexell d. Oncoimmunology. 2023 Mar 1;12(1):2184130. doi: 10.1080/2162402X.2023.2184130. eCollection 2023. Oncoimmunology. 2023. PMID: 36875552 Free PMC article.
Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.
Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D. Braekeveldt N, et al. Among authors: bexell d. Cancer Res. 2018 Oct 15;78(20):5958-5969. doi: 10.1158/0008-5472.CAN-18-0527. Epub 2018 Aug 28. Cancer Res. 2018. PMID: 30154149
43 results